Your browser doesn't support javascript.
loading
[Intermediate-risk prostate cancer treated with exclusive external irradiation: Focus on anatomical sites of recurrence in two French trials]. / Cancer de la prostate de risque intermédiaire traité par irradiation externe exclusive : focus sur les sites anatomiques de récidive dans deux essais français.
Langé, M; Magné, N; Zhou, K; Bellanger, M; Latorzeff, I; Pommier, P; Martin, E; Paumier, A; Béra, G; Supiot, S.
Afiliação
  • Langé M; Département de radiothérapie, institut de cancérologie de l'Ouest, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
  • Magné N; Département de radiothérapie, institut de cancérologie de la Loire, 42270 Saint-Priest-en-Jarez, France.
  • Zhou K; Département de sciences humaines et sociales, institut de cancérologie de l'Ouest, boulevard J.-Monod, 44800 Saint-Herblain, France.
  • Bellanger M; Département de sciences humaines et sociales, institut de cancérologie de l'Ouest, boulevard J.-Monod, 44800 Saint-Herblain, France.
  • Latorzeff I; Département de radiothérapie, Oncorad clinique Pasteur, 31300 Toulouse, France.
  • Pommier P; Département de radiothérapie, centre Léon-Bérard, 69008 Lyon, France.
  • Martin E; Département de radiothérapie, centre Georges-François-Leclerc, 21000 Dijon, France.
  • Paumier A; Département de radiothérapie, institut de cancérologie de l'Ouest, 49000 Angers, France.
  • Béra G; Département de radiothérapie, hôpital du Scorff, 56322 Lorient, France.
  • Supiot S; Département de radiothérapie, institut de cancérologie de l'Ouest, boulevard Jacques-Monod, 44800 Saint-Herblain, France; Centre de recherche en cancérologie Nantes-Angers (CRCNA), UMR 1232 Inserm-6299 CNRS, institut de recherche en santé de l'université de Nantes, 8, quai Moncousu, BP 70721, 44007
Cancer Radiother ; 26(5): 647-653, 2022 Sep.
Article em Fr | MEDLINE | ID: mdl-35715355
ABSTRACT

PURPOSE:

Retrospective description of anatomical sites of relapse based on (18F)-choline PET-CT, (68Ga)-prostatic specific-membrane antigen PET-CT, bone scan, and prostate magnetic resonance imaging (MRI) data. MATERIALS AND

METHODS:

From two French prospective cohorts, patients treated with exclusive radiotherapy for an intermediate-risk cancer were identified during their follow-ups. They were included if they presented a rising of the prostate-specific antigen (PSA) associated with the realization of an imaging showing the sites of recurrences.

RESULTS:

Two hundred and sixty-three patients were included. After a median follow-up of 76 months (interquartile range [IQR] 67-95), 65 patients had biochemical recurrence and positive imaging. The median nadir PSA was 0.6ng/mL and the median PSA at recurrence was 3.4ng/mL. A single lesion was found in 48% of cases, 2 to 4 lesions in 43% of cases and more than 4 lesions in 9% of cases. The sites of relapse identified were prostate (37/65), prostate only (19/65), seminal vesicles (9/65) Pelvic nodes (35/65), extrapelvic nodes (15/65) and bone (13/65).

CONCLUSIONS:

The majority of relapses presented as a single lesion localized in the pelvis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Idioma: Fr Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Idioma: Fr Ano de publicação: 2022 Tipo de documento: Article